

HE UNITED STATES PATENT AND TRADEMARK OFFICE

Karin Butz et al.

Title:

LIVIN-SPECIFIC siRNAs FOR THE TREATMENT OF

THERAPY-RESISTANT TUMORS

Appl. No.:

10/553,355

International Filing Date:

04/15/2004

371(c) Date:

07/05/06

Examiner:

Dana H. Shin

Art Unit:

1635

Confirmation No.:

6994

AMENDMENT TRANSMITTAL

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

- Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a [X]previous assertion of Small Entity status.
- Assertion of Small Entity status is enclosed.
 - The fee required for additional claims is calculated below: [X]

		Claims				Extra				
		As		Previously		Claims				Additional
		Amended		Paid For		Present		Rate		Claims Fee
T	otal Claims:	13	-	24	=	0	x	\$50.00	=	\$0.00
]	Independent Claims:	3	-	8	=	0	x	\$200.00	=	\$0.00
	First p	resentation	of an	y Multiple I	Depen	dent Claims:	+	\$360.00	=	\$0.00
						CLAIMS	FEI	ETOTAL	=	\$0.00

[X] Applicants hereby petition for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

[X] Extension for response filed w	ithin the first month:	\$120.00	\$120.00		
[] Extension for response filed w	ithin the second month:	\$450.00	\$0.00		
[] Extension for response filed w	ithin the third month:	\$1,020.00	\$0.00		
[] Extension for response filed w	ithin the fourth month:	\$1,590.00	\$0.00		
[] Extension for response filed w	ithin the fifth month:	\$2,160.00	\$0.00		
	EXTENSIO	N FEE TOTAL:	\$120.00		
[] Statutory Disclaimer Fee under	er 37 C.F.R. 1.20(d):	\$130.00	\$0.00		
•	CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL:				
[X] Sm	Small Entity Fees Apply (subtract ½ of above):				
	Extension Fees	Previously Paid:	\$0.00		
		TOTAL FEE:	\$60.00		

A credit card payment form in the amount of \$60.00 is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

If any extensions of time are needed for timely acceptance of papers submitted herewith, applicants hereby petition for such extension under 37 C.F.R. §1.136 and authorize payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone:

(202) 672-5538

Facsimile:

(202) 672-5399

Michele M. Simkir

Attorney for Applicants

Registration No. 34,717

المدورة المعالم المعالم

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 37 CFR §1.821(g). Extensions of time may obtained under the provisions of 37 CFR 1.136(a).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. §§1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. §§1.821-1.825. Applicant attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 111 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a Sequence Listing as required by 37 C.F.R. §1.821(c).
	3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. §1.821(e).
	4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. §1.822 and/or 1.823, as indicated on the attached copy of the marked-up Raw Sequence Listing.
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. §1.825(d).
	The paper copy of the Sequence Listing is not the same as the computer readable from of the Sequence Listing as required by 37 C.F.R. §1.821(e).
	7. Other:
Ap	plicant Must Provide:
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the Sequence Listing. (If the unidentified sequences are not provided on the CRF)
X	An initial or <u>substitute</u> paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification. (If the unidentified sequences are not provided in the paper copy)
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. §1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). (If a new paper and/or CRF are required)
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 centIn Software Program Support Technical Assistance
	To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY